

# **PRISM MEDICO AND PHARMACY LIMITED**

CIN: L24100HP2002PLC009299; Email Id: investorgrievancewmcl@gmail.com  
Registered Office: Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh-173030.

Date: 13.02.2024

To,  Department of Corporate Services, <b>BSE LIMITED</b> P. J. Towers, Dalal Street, Mumbai, Maharashtra-400001.  <b>ISIN : INE730E01016</b> <b>Scrip Code: 512217</b>	To,  Listing Department, <b>Metropolitan Stock Exchange of India Limited</b> <b>(MSEI)</b> Vibgyor Towers, 4 <sup>th</sup> Floor, Plot Number C 62, G - Block, Opposite Trident Hotel, Bandra Kurla Complex, Bandra (E), Mumbai, Maharashtra-400098. <b>SYMBOL: PRISMEDI</b>
---	--

**Subject: Outcome of the Board Meeting - Disclosure under Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

Pursuant to Regulation 30 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform you that the Board of Directors of the company at their meeting held today (i.e. 13<sup>th</sup> February, 2024) which commenced at 03:00 P.M. and concluded at 04:00 P.M. have inter alia approved the following:

- The Board considered and approved the Unaudited Standalone Financial Results of the company for the quarter ended 31<sup>st</sup> December, 2023 alongwith the Limited Review Report duly signed by the Auditors of the company.

You are requested to kindly take the same on record and oblige.

Thanking You.

Yours Truly,

**FOR PRISM MEDICO AND PHARMACY LIMITED**



**DAVENDER SINGH**  
**DIRECTOR**  
**DIN: 09447213**

# PRISM MEDICO AND PHARMACY LIMITED

CIN: L24100HP2002PLCO09299; EMAIL ID: INVESTORGRIEVANCEWMCL@GMAIL.COM

REGISTERED OFFICE: SUKETI ROAD, KALA AMB, SIRMAUR, HIMACHAL PRADESH-173030

## STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2023 (In Lakhs)

PARTICULARS	Quarter Ended			Year to date 31.12.2023	Year to date 31.12.2022	Year Ended (Audited)	Year Ended (Audited)
	31.12.2023	30.09.2023	31.12.2022			31.03.2023	31.03.2022
<b>I Income</b>							
Revenue from operations	274.73	3.27	-	277.99	-	127.06	844.38
Other income	0.03	1.06	-	2.72	-	0.17	-
<b>Total income from operations</b>	<b>274.76</b>	<b>4.33</b>	<b>-</b>	<b>280.71</b>	<b>-</b>	<b>127.23</b>	<b>844.38</b>
<b>II Expenses</b>							
Cost of material consumed	239.58	5.07	-	244.65	-	114.07	1,055.18
Change in inventories	-	-	-	-	-	-	(192.39)
Employee benefit expenses	0.94	0.77	0.51	2.22	4.03	4.66	19.04
Finance costs	0.40	-	-	0.70	-	0.03	0.04
Depreciation and amortization expenses	0.13	0.13	0.33	0.39	0.66	0.66	0.86
Other expenses	14.74	3.79	1.86	28.11	7.93	18.03	11.55
<b>Total expenses</b>	<b>255.79</b>	<b>9.76</b>	<b>2.70</b>	<b>276.07</b>	<b>12.62</b>	<b>137.45</b>	<b>894.28</b>
<b>III Profit/(Loss) before exceptional items and tax</b>	<b>18.97</b>	<b>(5.43)</b>	<b>(2.70)</b>	<b>4.64</b>	<b>(12.62)</b>	<b>(10.22)</b>	<b>(49.90)</b>
<b>IV Exceptional items</b>	-	-	-	-	-	-	-
<b>V Profit/(Loss) before Tax</b>	<b>18.97</b>	<b>(5.43)</b>	<b>(2.70)</b>	<b>4.64</b>	<b>(12.62)</b>	<b>(10.22)</b>	<b>(49.90)</b>
<b>VI Tax expenses</b>							
a) Current tax	-	-	-	-	-	-	-
b) Deferred tax	-	-	0.0400	-	0.080	2.59	12.90
b) Mat Credit	-	-	-	-	-	-	-
<b>VII Net Profit/(Loss) for the period/year</b>	<b>18.97</b>	<b>(5.43)</b>	<b>(2.74)</b>	<b>4.64</b>	<b>(12.70)</b>	<b>(7.63)</b>	<b>(37.00)</b>
<b>VIII Other comprehensive income (net of tax)</b>							
Items that will not be reclassified to profit or loss:							
i) Remeasurement of post employment benefit obligations	-	-	-	-	-	-	-
ii) Prior period income adjustment (Net of tax)	-	-	-	-	-	-	-
<b>Total other comprehensive income</b>	-	-	-	-	-	-	-
<b>IX Total comprehensive income for the period/year (VII+VIII)</b>	<b>18.97</b>	<b>(5.43)</b>	<b>(2.74)</b>	<b>4.64</b>	<b>(12.70)</b>	<b>(7.63)</b>	<b>(37.00)</b>
<b>X Paid-up equity share capital (face value of the share shall be indicated)</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>	<b>606.34</b>
<b>XI Other equity (excluding revaluation reserve)</b>	914.45	895.48	609.75	914.45	609.75	909.81	649.13
<b>XII EPS in Rs. (Face Value of Rs.10/- each)*</b>							
- Basic	0.0031	(0.0009)	(0.0005)	0.0008	(0.0021)	(0.0013)	(0.0061)
- Diluted	0.0031	(0.0009)	(0.0005)	0.0008	(0.0021)	(0.0013)	(0.0061)

**Notes:**

- The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 13.02.2024 after being reviewed by the Audit Committee.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company is having single segment in accordance with IND AS 108 "Operating Segments" and therefore segment reporting is not applicable to the company.

**FOR AND ON BEHALF OF THE BOARD  
PRISM MEDICO AND PHARMACY LIMITED**

*Davender Singh*

**DAVENDER SINGH  
DIRECTOR  
DIN: 09447213**

Place : Kala Amb, Himachal Pradesh.  
Date : 13th February, 2024.



# Harjeet Parvesh & Company

CHARTERED ACCOUNTANTS

(A PEER REVIEWED FIRM)

## Limited Review Report on Standalone Financial Results

### To Board of Directors of M/s Prism Medico & Pharmacy Limited

We have reviewed the Standalone Un-Audited Financial Result of M/s. Prism Medico And Pharmacy Ltd having its Regd. Office at Suketi Road, Kala Amb, Sirmaur, Himachal Pradesh – 173030 for the Quarter ended 31<sup>st</sup> December 2023 (“the Statement”) attached here with, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the Securities and Exchange Board of India ('SEBI') from time to time.

This statement is the responsibility of company’s Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagement to “Review of Interim Financial Information performed by the independent auditor of the entity” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material mis-statement. A review is limited primarily to inquiries of company personal and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Standalone Un-audited Financial Result prepared in accordance with applicable Accounting Standards i.e Indian Accounting Standards ('Ind AS') prescribed under section 133 of Companies Act, 2013, read with relevant rules issued there under and others recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Date :13.02.2024

UDIN:- 24547759BKFMNA2956

House No. 1122, Sector 71, Mohali

Mobile : 096460-27023, 098120-27023 | E-mail : harjeetca@yahoo.com



Scanned with OKEN Scanner